首页>
外文期刊>The Canadian journal of urology
>Re: Tutrone RF, Schiff W. Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. Can J Urol 2020;27(3):10213-10219.
【24h】
Re: Tutrone RF, Schiff W. Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. Can J Urol 2020;27(3):10213-10219.
展开▼
机译：Re: Tutrone RF, Schiff W. Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. Can J Urol 2020;27(3):10213-10219.
In a recent publication, Tutrone et al described and compared 1-month postoperative patient experiences and clinical outcomes following treatment for benign prostatic hyperplasia (BPH) between two minimally invasive procedures: UroLift prostatic urethral lift (PUL) and Rezum. The short-term outcomes of these two ambulatory procedures are undoubtedly important, notably for patientcounselling and peri-procedural preparation and expectations. Rezum is an emerging therapeutic, using convective radiofrequency water vapor thermal therapy to gradually cause localized cell necrosis in the prostatic tissue over a 3-month process. Early studies have shown promising clinical outcomes with low complication rates, good preservation of sexual function for prostate sizes of 30 cc-80 cc, and strong 5 year durability (4% BPH surgical retreatment rate).2 Moreover, PUL is another novel procedure involving delivery of several implants through the urethra, thus physically retracting obstructing prostate lobes. Through mechanical action, these implants allow for more immediate relief of symptoms with few side-effects.3 In this study, the authors conclude significantly better 1-month functional outcomes and faster recovery for UroLift when compared to Rezum. While meaningful, we believe that this study must be interpreted by the readership with great caution due its limitations.
展开▼
